The Institut du Cancer Courlancy in Reims, France, prepares to acquire the ZAP-X platform for advanced gyroscopic radiosurgery

The site will be one of the first in Europe to offer a pioneering innovation in the non-invasive treatment of brain tumors.

SAN CARLOS, California, September 27, 2022–(COMMERCIAL WIRE)–ZAP Surgical Systems, Inc. today announces that the Institut du Cancer Courlancy (ICC) in Reims, France, will acquire the latest advancement in non-invasive treatments for brain tumors, ZAP-X® Gyroscopic Radiosurgery®, to complete its technical platform of cancer treatment technologies.

This press release contains multimedia elements. See the full press release here:

ZAP-X® Gyroscopic Radiosurgery Platform® (Graphic: Business Wire)

Through collaboration between the radio-oncology and neurosurgery teams, the institute intends to consolidate its status as a regional center of excellence in oncology by dedicating the ZAP-X to treatments for intracranial indications, thus completing its entire park of modern radiotherapy accelerators. , optimized for the treatment of lung, breast, prostate and other types of cancer.

Radiosurgery is an effective and appropriate treatment for many brain cancers, including primary and metastatic brain tumors. For eligible indications, radiosurgery is a noninvasive and painless alternative to expensive and often disabling surgeries.

Designed specifically for cranial radiosurgery, the ZAP-X System leverages robotic surgery technology and innovative gyroscopic mobility to focus high-intensity radiation on tumor targets while minimizing indirect radiation exposure to normal brain tissue. and in healthy adjacent organs.

“Unlike conventional radiation therapy, cranial radiosurgery requires great precision to preserve the patient’s neurocognitive function and protect radiosensitive organs such as the eyes, optic nerves, and brain stem,” says Dr. Philippe Colin, radiation oncologist at ICC, specialized in neurological applications and responsible for the ZAP-X program. “These meticulous requirements are ideally met by dedicated radiosurgery technologies, such as the ZAP-X platform, which aim to provide greater control and precision of radiation delivery.”

“The team intends to treat around 500 radiosurgery patients per year, focusing above all on the treatment of metastatic and benign brain tumors,” adds Professor Claude-Fabien Liter, a neurosurgeon at the Center Hospitalier Universitaire de Reims. “We also plan to build on our expertise in functional radiosurgery, including radiosurgical thalamotomy, through our experience of more than 300 frameless trigeminal neuralgia treatments.”

The ZAP-X system is the first new dedicated cranial radiosurgery platform in nearly a century. Before ZAP-X, advanced radiosurgery often required hospitals to administer large amounts of expensive and volatile cobalt-60 for the production of the radiosurgical beam. ZAP-X eliminates this historical need by using state-of-the-art linear accelerator technology and also eliminates the burdens of perpetual source decay and recurring isotope replacement costs.

For more information, visit the website of Surgical Zap and follow us on LinkedIn Y Twitter. Find detailed system videos on the Zap Surgical YouTube Page.

About ZAP Surgical Systems, Inc.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. Dr. Adler, CEO of ZAP, is also the Dorothy and TK Chan Professor Emeritus of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also credited as the inventor of the CyberKnife system.®, and founder of Accuray, Inc. The ZAP-X platform incorporates a unique bunker-less design, which eliminates the need for costly shielded treatment rooms. ZAP-X also uses a modern linear accelerator, which eschews the traditional use of cobalt-60.

The text of the press release resulting from a translation should not be considered official in any way. The only authentic version of the press release is the press release in its original language. The translation will always have to be compared with the original text, which will set a precedent.

See the source version on


Mark Arnold, ZAP Surgical Systems, Inc.
Senior Vice President of Marketing
+1 650 492 7797, ext. 101

Herve Servajean, Qualimedis S.A.S.
Managing Director
+ 33 6 23 57 24 29

Leave a Comment

Your email address will not be published. Required fields are marked *